Equities analysts predict that Kindred Biosciences Inc (NASDAQ:KIN) will announce $1.55 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Kindred Biosciences’ earnings, with the lowest sales estimate coming in at $1.40 million and the highest estimate coming in at $1.70 million. Kindred Biosciences reported sales of $640,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 142.2%. The business is scheduled to announce its next earnings report after the market closes on Tuesday, November 12th.

On average, analysts expect that Kindred Biosciences will report full year sales of $5.25 million for the current financial year, with estimates ranging from $4.60 million to $5.90 million. For the next fiscal year, analysts anticipate that the company will post sales of $15.75 million, with estimates ranging from $8.80 million to $22.70 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Kindred Biosciences.

Several research firms recently weighed in on KIN. BidaskClub raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. Zacks Investment Research raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Kindred Biosciences in a research note on Wednesday, July 31st. ValuEngine raised Kindred Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 15th. Finally, B. Riley lowered Kindred Biosciences from a “buy” rating to a “neutral” rating and cut their price target for the company from $18.00 to $8.50 in a research note on Tuesday, July 16th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $14.28.

NASDAQ:KIN opened at $8.44 on Tuesday. The stock’s 50-day simple moving average is $7.57 and its 200 day simple moving average is $7.81. The firm has a market capitalization of $345.30 million, a PE ratio of -5.28 and a beta of 0.45. The company has a quick ratio of 10.79, a current ratio of 11.36 and a debt-to-equity ratio of 0.01. Kindred Biosciences has a twelve month low of $5.96 and a twelve month high of $14.00.

Several hedge funds have recently made changes to their positions in KIN. Morgan Stanley lifted its stake in shares of Kindred Biosciences by 67.4% in the second quarter. Morgan Stanley now owns 1,901,961 shares of the biopharmaceutical company’s stock worth $15,843,000 after acquiring an additional 765,748 shares during the period. BlackRock Inc. lifted its stake in shares of Kindred Biosciences by 21.6% in the second quarter. BlackRock Inc. now owns 2,393,085 shares of the biopharmaceutical company’s stock worth $19,934,000 after acquiring an additional 425,237 shares during the period. Dalton Greiner Hartman Maher & Co. acquired a new position in shares of Kindred Biosciences in the third quarter worth approximately $971,000. Allianz Asset Management GmbH lifted its stake in shares of Kindred Biosciences by 27.8% in the second quarter. Allianz Asset Management GmbH now owns 433,131 shares of the biopharmaceutical company’s stock worth $3,608,000 after acquiring an additional 94,091 shares during the period. Finally, General American Investors Co. Inc. lifted its stake in shares of Kindred Biosciences by 10.0% in the second quarter. General American Investors Co. Inc. now owns 494,327 shares of the biopharmaceutical company’s stock worth $4,118,000 after acquiring an additional 44,753 shares during the period. 68.18% of the stock is currently owned by hedge funds and other institutional investors.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.